Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “buy” rating reiterated by stock analysts at Mizuho in a research report issued to clients and investors on Friday. They presently have a $54.00 target price on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 50.42% from the company’s previous close.
Several other brokerages have also recently issued reports on RVNC. Guggenheim restated a “buy” rating and issued a $44.00 target price on shares of Revance Therapeutics in a report on Thursday. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Thursday. Barclays set a $40.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 19th. SunTrust Banks upped their price target on shares of Revance Therapeutics to $53.00 and gave the company a “buy” rating in a research report on Friday, December 8th. Finally, Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $43.33.
Shares of Revance Therapeutics (RVNC) traded up $0.20 during trading on Friday, hitting $35.90. 373,300 shares of the stock traded hands, compared to its average volume of 405,200. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45. The firm has a market cap of $1,110.00, a PE ratio of -9.42 and a beta of 1.62.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the transaction, the chief executive officer now owns 133,188 shares in the company, valued at approximately $3,321,708.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark J. Foley acquired 20,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $26.96 per share, with a total value of $539,200.00. Following the transaction, the director now owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. In the last quarter, insiders sold 36,426 shares of company stock valued at $956,026. 18.86% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Pura Vida Investments LLC purchased a new position in Revance Therapeutics during the 3rd quarter worth $1,378,000. Schwab Charles Investment Management Inc. raised its position in Revance Therapeutics by 4.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 117,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 5,501 shares during the last quarter. EAM Investors LLC raised its position in Revance Therapeutics by 113.9% during the 3rd quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock worth $1,998,000 after buying an additional 38,621 shares during the last quarter. SG Americas Securities LLC purchased a new position in Revance Therapeutics during the 3rd quarter worth $144,000. Finally, Alps Advisors Inc. raised its position in Revance Therapeutics by 11.1% during the 3rd quarter. Alps Advisors Inc. now owns 30,351 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 3,027 shares during the last quarter. Institutional investors own 76.69% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.